Advanced Bio (Suzhou) Co., Ltd.

Advanced Biotherapeutics, Ltd. is a high-tech company that focuses on the R&D， production and application of immune cell therapy for tumors. Adhering to the concept of "life first, health for millions of families", the company keeps going on to develop new type of cellular drug for cancer patients that are "effective and affordable" for the majority of people. The company was founded in June 2020 and is headquartered in the BioBay in Suzhou Nano-tech Industry Park.

The core scientific team is led by Dr. Zhongwei Xu, a former senior researcher in University of Pennsylvania. Dr. Xu  is also a visiting professor in the Department of Immunology at Peking University, a distinguished professor at Translational Hepatology Institute at Capital Medical University,. The team includes other more international senior immunotherapy experts from famous American immunotherapy centers. Many of them have rich experiences in the field of cell and gene therapy , as well as drug application and review for FDA.

Dr. Xu has been engaged in LAK and TIL cell therapy since 1993. He started the research and development of CAR-T cell therapy in Japan in 1996, and is one of the  first Chinese scientists engaged in the development of CAR-T cell in the world. In 2005, he was appointed as the first project manager for the R&D of CD19-CAR-T cell therapy in Dr. Carl June's team. During that time, he made special contributions to the first human CAR-T drug approved by the FDA and the successful treatment of Emily Whitehead, an American pediatric patient who has leukemia. Their relevant findings, along with the CTLA-4 and PD-1 discovery which won the Nobel Prize in 2018, were rated by 《Science》 magazine as the first in the world’s Top10 breakthroughs in science and technology in 2013.

We innovatively carried out the HLA-Haploidentical Allogeneic CAR-T protocol in Beijing in 2016 and successfully treated patients with relapsed and refractory acute lymphoblastic leukemia. The treatment opens a new way for allogeneic CAR-T cell therapy. This clinical approach is called by the industry as “Beijing Approach” of allogeneic CAR-T immunotherapy . It has brought our country’s technological innovation of allogeneic CAR-T cell therapy to the forefront of world. The clinical treatment complete response (CR) rate was greater than 90%. Relapse free survival of the first patient is over 4 years, making the world record of disease-free survival with allogeneic CAR-T therapy.

Advanced Biotherapeutics makes full use of the advantages of talents and technical resources of immune cell therapy research at home and abroad. Taking the Suzhou R&D platform as the core, we form a development model of "international multi-directional cooperation dominated by R&D", and spare no effort to build a national enterprise in the domestic immune cell therapy industry.

The company always takes the life and health of patients as its primary core value. Through the R&D of new product and process improvement, the company provides patients with safer, more effective and better-quality immune cell products to meet urgent treatment needs.